MedTrace Logo

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

NCT05737303 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 538

Last updated 2025-02-11

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.

Conditions

  • Epithelial Ovarian Carcinoma Stage III
  • Epithelial Ovarian Carcinoma Stage IV
  • Fallopian Tube Carcinoma Stage III
  • Fallopian Tube Carcinoma Stage IV
  • Primary Peritoneal Carcinoma Stage III
  • Primary Peritoneal Carcinoma Stage IV

Interventions

DRUG

nab-paclitaxel combined with carboplatin

Nab-Paclitaxel/carboplatin q3weeks Nab-Paclitaxel 260 mg/m² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel/carboplatin weekly Dose-dense Nab-Paclitaxel 100 mg/m2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles Paclitaxel 175 mg/m² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles Paclitaxel weekly/carboplatin weekly Paclitaxel 60 mg/m2 followed by carboplatin AUC（area under the curve）2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)

Sponsors & Collaborators

  • Jiaxing Maternity and Child Health Care Hospital

    collaborator OTHER

  • Zhejiang University

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Second Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Ningbo No. 1 Hospital

    collaborator OTHER

  • Ningbo Women & Children's Hospital

    collaborator OTHER

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • Women's Hospital School Of Medicine Zhejiang University

    lead OTHER

Principal Investigators

  • Yaxia Chen, MD · Study Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-27
Primary Completion
2025-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05737303 on ClinicalTrials.gov